Latest news with #AdamClarke
Times
22-05-2025
- Sport
- Times
Mo Farah's Urunn: AI-powered running app to rival Strava
Sir Mo Farah, the Olympic runner who hung up his trainers in 2023, is launching an app that draws up personalised fitness plans for novices and professionals alike. The four-time Olympic gold medallist has co-founded Urunn alongside Adam Clarke, a former professional runner who won the Manchester marathon last year. The mobile app designs bespoke running regimes based on a user's fitness, pace and goals. Farah said that it was a chance to pass on some of his, and Clarke's, experience to runners of all levels. 'We are trying to give back what we have learnt to everyone — whether you are Joe Jogger just starting to run, or whether you are elite,' he said. He added that the app was meant to take away
National Post
29-04-2025
- Business
- National Post
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer Research Ⓡ (AACR) 116th Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois, taking place April 25 to 30, 2025. Article content Targeting prostate-specific membrane antigen (PSMA) with a CD3 TCE could provide an effective treatment option for metastatic castration-resistant prostate cancer (mCRPC). In its poster presentation at AACR, AbCellera demonstrated that its PSMA x CD3 TCEs show promising preclinical activity, including: Article content Potent in vitro tumor-cell killing, with one molecule showing ~10x higher EC 50 than benchmark Sustained in vitro activity across four rounds of serial T-cell killing Preclinical in vivo efficacy, with significant tumor growth inhibition in a xenograft mouse model Potential for enhanced potency when combined with costimulatory PSMA x CD28 bispecifics Article content 'The preclinical data package presented at AACR is the first demonstration that our novel CD3-binders can be used to generate molecules with potent anti-tumor efficacy in vivo, ' said Adam Clarke, Ph.D., SVP, Discovery at AbCellera. 'The poster underscores the strength of our TCE platform strategy, which is to combine diverse CD3- and tumor-binding antibodies and use empirical testing to engineer optimized therapeutic candidates. In addition, the data strongly support the use of costimulation to further increase anti-tumor activity.' Article content CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality and costimulatory building blocks to enhance efficacy for difficult-to-treat cancers. Article content About AbCellera Biologics Inc. Article content AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit Article content This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Article content In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations,' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Article content Article content Article content Article content Article content Article content
Daily Mirror
25-04-2025
- Sport
- Daily Mirror
Manchester Marathon 2025 start time, route map, road closures and more
The Manchester Marathon takes place on Sunday and here is all you need to know about the big race A record-breaking 36,000 people will be on the start line on Sunday to tackle the 26.2 miles of the adidas Manchester Marathon. Places for the race sold out more than five months ago - all of the hard work is done and now it's time for participants to take a well-deserved victory lap. It is the UK's second biggest marathon after London and one of the largest in Europe. The enthusiastic Mancunian crowds make it stand out from the rest, ensuring it's an unforgettable experience for those taking to the streets and providing that extra boost to get them to the finish line. Here is all you need to know ahead of the annual event. When is the Manchester Marathon and what time does it start? The Manchester Marathon takes place on Sunday, April 27. The race starts at 9am with the elites, then waves every 10 minutes, with the final participants expected to get underway at 11.30am. What is the route? Manchester Marathon is a favourite amongst runners due to its flat and fast course, making it perfect to attempt a personal best time. Adam Clarke won last year's race in a blistering 2:16:29. It starts by Manchester United 's Old Trafford stadium before heading down the Chester Road to Stretford, Sale and then Altrincham around the halfway mark. Runners then head back through Baguley, Sale Moor, Chorlton, Whalley and Hume before reaching the new finishing line on Oxford Road. Road closures There will be some roads closed in Manchester city centre near Oxford Road on Saturday. Closures on the race route starts from 4am on Sunday morning. A full list can be found here. All roads are expected to reopen by 7pm on Sunday evening. Results Manchester Marathon results can be found here. Participants will get a personalised chipped time - which reflects when they crossed the start and finish lines. How to enter The Manchester Marathon sold out this year in record time, but you can register your interest for next year's event, which takes place on Sunday, April 19, here to gain priority access.
BBC News
23-04-2025
- Sport
- BBC News
Manchester Marathon: All you need to know ahead of Sunday's race
More than 35,000 runners are expected to take part in this weekend's Manchester Marathon. Organisers are expecting entrants from all over the world to pound the city's streets for the annual race on Sunday, which this year has a new finish line outside the University of Manchester on Oxford Road. Runners and spectators have been urged to plan their journeys well in advance because the main roads around Trafford will be closed for much of the buses will be diverted, while transport bosses also expect Metrolink services to be very busy. Where is the route? The course, which loops around South Manchester, starts by Old Trafford football stadium before turning back on to Chester Road towards Sale, and then arriving in will then turn back, passing through Baguley and back through Sale, before passing Chorlton, Whalley and Hulme. The finishing line this year has been moved to Oxford Road. When does it start? The first batch of runners, which includes the elite athletes expected to battle it out for a podium finish, will set off at 09:00 BST. Groups will then be released at 10-minute intervals until the last cohort sets off at 11:30. Last year's winner Adam Clarke completed the 26.2 miles (42.2km) in two hours, 15 minutes and 35 said all roads are due to reopen by 19:00, with many becoming accessible sooner. Which roads are closed? Part of Oxford Road from Hulme Street to Grafton Street, as well as several surrounding roads in Manchester city centre will shut on Saturday between 08:00 BST and midday ahead of the race. On marathon day, the route will start to shut from 04:00 BST along Chester Road and Bridgewater Way, before the rest of the route begins to close. Several vehicle crossing points have been put in place around the course, along with diversions, while parking has been suspended on a number of have released a map with all the closures and timings here. Can I use public transport? The closures will see buses diverted across Manchester and for Greater Manchester has urged people to use Metrolink services but warned marathon Sunday is "one of the busiest days of the year" for using the trams, particularly in the morning. Thousands of competitors are expected to use services early, while later in the day spectators will be moving around the network to cheer runners on. Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Yahoo
18-04-2025
- Business
- Yahoo
Leidos Holdings (NYSE:LDOS) Commits US$10 Million To Transform AI In Health Care Detection
Leidos Holdings recently initiated a significant collaboration with the University of Pittsburgh, investing $10 million to advance AI applications in disease detection and management. This aligns with their longstanding commitment to health technology innovations. Meanwhile, the executive appointments of Daryle Lademan and Adam Clarke bring fresh leadership to their strategic and European operations, potentially stabilizing investor confidence. The successful flight test of the Black Arrow missile further underscores their advancements in the defense sector. These developments, while impactful, occur as the market remains flat in the short term with a 5.7% annual increase, leading to a flat stock performance last month. Be aware that Leidos Holdings is showing 1 weakness in our investment analysis. Find companies with promising cash flow potential yet trading below their fair value. The recent developments at Leidos Holdings, including the collaboration with the University of Pittsburgh and executive leadership changes, align closely with the company's NorthStar 2030 strategy. This strategy emphasizes IT modernization and increased privatization, which are poised to impact revenue positively in healthcare and defense sectors. The collaboration could enhance AI capabilities, potentially boosting revenues through new AI-driven offerings. Additionally, solidified leadership in strategic and European operations may bolster investor confidence, contributing to future earnings stability. In a longer-term context, Leidos Holdings delivered a total return of 51.05% over the past five years, showcasing consistent growth despite recent flat stock performance. This compares favorably against the Professional Services industry's 7.4% one-year return. Such returns indicate resilience and a focus on transformation that has supported sustained growth. In the same year, Leidos outperformed the broader US market's 5.7% one-year return, demonstrating its relative strength amid competitive pressures. While the company faces potential competition and budgetary uncertainties, the successful test of defense technology and strategic share repurchases point to robust earnings forecasts supported by a strong contract backlog, including the notable $4.1 billion IFPC Enduring Shield contract. Current share price movements, with a 17.6% gap to the consensus price target of US$169.81, reflect market caution but also suggest potential upside if growth targets are achieved. Analysts' expectations hinge on Leidos meeting or exceeding projected revenue of $18.40 billion and earnings of $1.50 billion by 2028, essential metrics influencing future valuations and shareholder returns. Learn about Leidos Holdings' historical performance here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LDOS. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
